We are live on ! Find out more
DRTX

DURATA THERAPEUTICS INC COM STK (DE)
DRTX

Delisted

DRTX was delisted on the 17th of November, 2014.

48 hedge funds and large institutions have $65.8M invested in DURATA THERAPEUTICS INC COM STK (DE) in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

19% more capital invested

Capital invested by funds: $55.4M → $65.8M (+$10.4M)

17% more funds holding

Funds holding: 4148 (+7)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
48
Holders Change
+7
Holders Change %
+17.07%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
22
Reduced
9
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$16.1M
DCM
2
Discovery Capital Management
Connecticut
$10.7M
Wellington Management Group
3
Wellington Management Group
Massachusetts
$8.79M +$261K +31,486 +3%
GPP
4
Great Point Partners
Connecticut
$4.6M +$4.22M +508,472 New
BC
5
Broadfin Capital
New York
$3.46M
BFA
6
BlackRock Fund Advisors
California
$3.36M +$357K +42,989 +13%
DM
7
Deerfield Management
New York
$2.5M -$3.95M -476,560 -63%
Vanguard Group
8
Vanguard Group
Pennsylvania
$2.31M +$4.79K +577 +0.2%
Millennium Management
9
Millennium Management
New York
$1.63M +$1.49M +180,175 New
Northern Trust
10
Northern Trust
Illinois
$1.6M +$499K +60,156 +52%
State Street
11
State Street
Massachusetts
$1.29M +$58.9K +7,106 +5%
BIT
12
BlackRock Institutional Trust
California
$1.25M +$81K +9,768 +8%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$904K +$829K +100,000 New
TAM
14
Tocqueville Asset Management
New York
$688K +$108K +13,000 +21%
BCM
15
Bridgeway Capital Management
Texas
$688K +$238K +28,650 +60%
Deutsche Bank
16
Deutsche Bank
Germany
$512K +$405K +48,868 +622%
TCIM
17
TIAA CREF Investment Management
New York
$474K +$16.3K +1,962 +4%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$465K +$25K +3,014 +6%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$439K -$2.65K -320 -0.7%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$426K +$91.4K +11,020 +31%
Bank of America
21
Bank of America
North Carolina
$420K +$147K +17,724 +62%
JP Morgan Chase
22
JP Morgan Chase
New York
$418K -$195K -23,549 -34%
BIM
23
BlackRock Investment Management
Delaware
$334K +$23.7K +2,853 +8%
SIP
24
Stoneridge Investment Partners
Pennsylvania
$278K +$255K +30,732 New
PAM
25
Paradigm Asset Management
New York
$226K +$207K +25,000 New

DRTX Hedge Fund Activity: Q3 2013 in Review

48 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in DURATA THERAPEUTICS INC COM STK (DE) (DRTX) for Q3 2013, worth a combined $65.8M — up 19% from $55.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new DRTX positions and 1 closed out — a net gain of 8 holders — while 22 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.49M. The largest seller was Deerfield Management, cutting an estimated $3.95M.

  • 48 institutional investors held DURATA THERAPEUTICS INC COM STK (DE) (DRTX) as of Q3 2013, up from 41 in Q2 2013.
  • Funds reported $65.8M of DURATA THERAPEUTICS INC COM STK (DE) stock for Q3 2013, up 19% quarter-over-quarter.
  • 9 funds opened new DURATA THERAPEUTICS INC COM STK (DE) positions in Q3 2013 and 1 closed out, a net change of +8 holders.
  • The largest DURATA THERAPEUTICS INC COM STK (DE) buyer in Q3 2013 was Millennium Management, an estimated $1.49M added.
  • The largest DURATA THERAPEUTICS INC COM STK (DE) seller in Q3 2013 was Deerfield Management, an estimated $3.95M sold.

Based on aggregated 13F filings for Q3 2013.